Monroe Capital Funds GPP-backed Cytovance with $20M
October 29, 2014
Monroe Capital has provided $20 million in debt financing to Great Point Partners-backed Cytovance Biologics. Monroe acted as sole lead arranger and administrative agent for the senior credit facility. Founded in 2003, Cytovance is a contract manufacturer of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies and cell-based therapeutic products.